iCAD, Inc. (NASDAQ:ICAD) Short Interest Up 28.5% in May

iCAD, Inc. (NASDAQ:ICAD - Get Free Report) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 397,400 shares, a growth of 28.5% from the April 30th total of 309,200 shares. Currently, 1.5% of the company's shares are sold short. Based on an average daily volume of 801,800 shares, the short-interest ratio is presently 0.5 days.

Analyst Ratings Changes

A number of brokerages have issued reports on ICAD. Laidlaw reissued a "hold" rating on shares of iCAD in a research note on Thursday, April 17th. Wall Street Zen started coverage on shares of iCAD in a research report on Tuesday, May 20th. They set a "sell" rating on the stock. BTIG Research cut iCAD from a "buy" rating to a "neutral" rating in a research note on Wednesday, April 16th. Finally, Craig Hallum cut iCAD from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th.

iCAD Trading Down 3.3%

Shares of NASDAQ ICAD traded down $0.13 during midday trading on Wednesday, reaching $3.77. The company's stock had a trading volume of 358,509 shares, compared to its average volume of 413,840. The company has a market cap of $103.57 million, a price-to-earnings ratio of -29.00 and a beta of 1.35. The company has a 50 day moving average price of $3.06 and a 200 day moving average price of $2.55. iCAD has a one year low of $1.18 and a one year high of $4.02.

iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The technology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. The firm had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.54 million. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.

Institutional Investors Weigh In On iCAD

Several hedge funds and other institutional investors have recently made changes to their positions in ICAD. Parkman Healthcare Partners LLC acquired a new stake in shares of iCAD in the first quarter worth $1,610,000. Informed Momentum Co LLC acquired a new position in iCAD during the first quarter worth $593,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in iCAD during the 1st quarter valued at about $505,000. Summit Trail Advisors LLC acquired a new position in shares of iCAD in the 4th quarter worth approximately $214,000. Finally, Jane Street Group LLC bought a new position in shares of iCAD in the first quarter valued at about $180,000. 24.61% of the stock is owned by institutional investors and hedge funds.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.